Study finds secukinumab effective for moderate to severe scalp psoriasis

 

Secukinumab is a safe and effective treatment option for patients with moderate to severe scalp psoriasis, according to Dr. Jerry Bagel of the Psoriasis Treatment Center of Central New Jersey, and his associates.

After 12 weeks of treatment with 300 mg of secukinumab, administered subcutaneously, 52.9% of the 50 patients who received secukinumab achieved a 90% reduction in their Psoriasis Scalp Severity Index score, and 35.3% achieved complete clearance of scalp psoriasis. Only 2% of the 47 patients in the placebo group achieved PSSI 90, and no one achieved complete clearance, in the phase 3b study.

copyright eenevski/Thinkstock

The most common adverse events in patients who received secukinumab, an interleukin-17A antagonist, were nasopharyngitis, upper respiratory tract infection, cough, and contact dermatitis. No serious adverse events occurred in patients receiving secukinumab; however, two patients who were initially in the study and receiving secukinumab discontinued because of moderate upper abdominal pain and mild psoriasis.

“These promising results demonstrate the possibility of establishing PSSI 90 as a new benchmark for scalp psoriasis treatment outcome,” the investigators noted. Secukinumab (Cosentyx) is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and in adult patients who are candidates for systemic therapy or phototherapy, and ankylosing spondylitis.

Find the study in the Journal of the American Academy of Dermatology (doi: 10.1016/j.jaad.2017.05.033).

[email protected]

 

Secukinumab is a safe and effective treatment option for patients with moderate to severe scalp psoriasis, according to Dr. Jerry Bagel of the Psoriasis Treatment Center of Central New Jersey, and his associates.

After 12 weeks of treatment with 300 mg of secukinumab, administered subcutaneously, 52.9% of the 50 patients who received secukinumab achieved a 90% reduction in their Psoriasis Scalp Severity Index score, and 35.3% achieved complete clearance of scalp psoriasis. Only 2% of the 47 patients in the placebo group achieved PSSI 90, and no one achieved complete clearance, in the phase 3b study.

copyright eenevski/Thinkstock

The most common adverse events in patients who received secukinumab, an interleukin-17A antagonist, were nasopharyngitis, upper respiratory tract infection, cough, and contact dermatitis. No serious adverse events occurred in patients receiving secukinumab; however, two patients who were initially in the study and receiving secukinumab discontinued because of moderate upper abdominal pain and mild psoriasis.

“These promising results demonstrate the possibility of establishing PSSI 90 as a new benchmark for scalp psoriasis treatment outcome,” the investigators noted. Secukinumab (Cosentyx) is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and in adult patients who are candidates for systemic therapy or phototherapy, and ankylosing spondylitis.

Find the study in the Journal of the American Academy of Dermatology (doi: 10.1016/j.jaad.2017.05.033).

[email protected]

 

Secukinumab is a safe and effective treatment option for patients with moderate to severe scalp psoriasis, according to Dr. Jerry Bagel of the Psoriasis Treatment Center of Central New Jersey, and his associates.

After 12 weeks of treatment with 300 mg of secukinumab, administered subcutaneously, 52.9% of the 50 patients who received secukinumab achieved a 90% reduction in their Psoriasis Scalp Severity Index score, and 35.3% achieved complete clearance of scalp psoriasis. Only 2% of the 47 patients in the placebo group achieved PSSI 90, and no one achieved complete clearance, in the phase 3b study.

copyright eenevski/Thinkstock

The most common adverse events in patients who received secukinumab, an interleukin-17A antagonist, were nasopharyngitis, upper respiratory tract infection, cough, and contact dermatitis. No serious adverse events occurred in patients receiving secukinumab; however, two patients who were initially in the study and receiving secukinumab discontinued because of moderate upper abdominal pain and mild psoriasis.

“These promising results demonstrate the possibility of establishing PSSI 90 as a new benchmark for scalp psoriasis treatment outcome,” the investigators noted. Secukinumab (Cosentyx) is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and in adult patients who are candidates for systemic therapy or phototherapy, and ankylosing spondylitis.

Find the study in the Journal of the American Academy of Dermatology (doi: 10.1016/j.jaad.2017.05.033).

[email protected]